1. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
- Author
-
Andrea Michelotti, Stefano Iacobelli, Giancarlo Bisagni, Patrizia Vici, Ilaria Ferrarini, Lucia Mentuccia, Corrado Ficorella, Isabella Sperduti, Stefania Gori, Riccardo Samaritani, Germano Zampa, Maria Mauri, Nicola Tinari, Michele Panebianco, Teresa Gamucci, Luca Moscetti, Clara Natoli, Laura Pizzuti, Michele De Tursi, and Antonino Grassadonia
- Subjects
Oncology ,Cancer Research ,Survival ,Receptor, ErbB-2 ,medicine.medical_treatment ,Gene Expression ,Kaplan-Meier Estimate ,Breast cancer ,Trastuzumab ,Antineoplastic Combined Chemotherapy Protocols ,Anthracyclines ,skin and connective tissue diseases ,Neoadjuvant therapy ,Hematology ,Carcinoma, Ductal, Breast ,General Medicine ,Middle Aged ,Neoadjuvant Therapy ,Treatment Outcome ,Chemotherapy, Adjuvant ,Female ,Taxoids ,Neoadjuvant ,medicine.drug ,Adult ,medicine.medical_specialty ,Standard of care ,Neoplasms, Hormone-Dependent ,Locally advanced ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,Internal medicine ,HER2 ,medicine ,Humans ,neoplasms ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Chemotherapy ,Original Paper ,Pathological complete response ,business.industry ,Retrospective cohort study ,medicine.disease ,Multivariate Analysis ,business - Abstract
Purpose Trastuzumab and chemotherapy is the current standard of care in HER2+ early or locally advanced breast cancer, but there are scanty literature data of its real world effectiveness. Methods We retrospectively reviewed 205 patients with HER2+ breast cancer diagnosed in 10 Italian Medical Oncology Units between July 2003 and October 2011. All patients received neoadjuvant systemic therapy (NST) with trastuzumab in association with chemotherapy. Many different chemotherapy regimens were used, even if 90 % of patients received schemes including anthracyclines and 99 % received taxanes. NST was administered for more than 21 weeks (median: 24) in 130/205 (63.4 %) patients, while trastuzumab was given for more than 12 weeks (median: 12 weeks) in 101/205 (49.3 %) patients. pCR/0 was defined as ypT0+ypN0, and pCR/is as ypT0/is+ypN0. Results pCR/0 was obtained in 24.8 % and pCR/is in 46.8 % of the patients. At multivariate logistic regression, nonluminal/HER2+ tumors (P
- Published
- 2013